ES2094694B1 - Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. - Google Patents

Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.

Info

Publication number
ES2094694B1
ES2094694B1 ES09500181A ES9500181A ES2094694B1 ES 2094694 B1 ES2094694 B1 ES 2094694B1 ES 09500181 A ES09500181 A ES 09500181A ES 9500181 A ES9500181 A ES 9500181A ES 2094694 B1 ES2094694 B1 ES 2094694B1
Authority
ES
Spain
Prior art keywords
compound
benzmidazole
obtaining
stable formulation
pharmaceutically stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES09500181A
Other languages
English (en)
Spanish (es)
Other versions
ES2094694A1 (es
Inventor
Rodes Montserrat Ballester
Boven Marinus Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Quimica SA
Original Assignee
Esteve Quimica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8289322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2094694(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Quimica SA filed Critical Esteve Quimica SA
Priority to ES09500181A priority Critical patent/ES2094694B1/es
Priority to US08/429,689 priority patent/US5626875A/en
Priority to IL11667396A priority patent/IL116673A/xx
Priority to AR10105196A priority patent/AR002702A1/es
Priority to IN104CA1996 priority patent/IN186596B/en
Priority to PCT/ES1996/000013 priority patent/WO1996023500A1/es
Priority to PT96901349T priority patent/PT773025E/pt
Priority to ES96901349T priority patent/ES2148725T3/es
Priority to EP99116334A priority patent/EP0993830B1/en
Priority to TW085100946A priority patent/TW503115B/zh
Priority to SI9630710T priority patent/SI0993830T1/xx
Priority to DE29623938U priority patent/DE29623938U1/de
Priority to SI9630226T priority patent/SI0773025T1/xx
Priority to HU9603014A priority patent/HU229219B1/hu
Priority to CA002184842A priority patent/CA2184842C/en
Priority to KR1019960704702A priority patent/KR100331290B1/ko
Priority to DE69634613T priority patent/DE69634613T2/de
Priority to AU45403/96A priority patent/AU4540396A/en
Priority to JP52327896A priority patent/JP4183746B2/ja
Priority to DK96901349T priority patent/DK0773025T3/da
Priority to PT99116334T priority patent/PT993830E/pt
Priority to DE69608767T priority patent/DE69608767D1/de
Priority to DK99116334T priority patent/DK0993830T3/da
Priority to ES99116334T priority patent/ES2238796T3/es
Priority to AT99116334T priority patent/ATE292967T1/de
Priority to AT96901349T priority patent/ATE193649T1/de
Priority to EP96901349A priority patent/EP0773025B1/en
Priority to ZA96683A priority patent/ZA96683B/xx
Priority to FI963916A priority patent/FI121730B/fi
Publication of ES2094694A1 publication Critical patent/ES2094694A1/es
Publication of ES2094694B1 publication Critical patent/ES2094694B1/es
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES09500181A 1995-02-01 1995-02-01 Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. Expired - Fee Related ES2094694B1 (es)

Priority Applications (29)

Application Number Priority Date Filing Date Title
ES09500181A ES2094694B1 (es) 1995-02-01 1995-02-01 Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US08/429,689 US5626875A (en) 1995-02-01 1995-04-27 Stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
IL11667396A IL116673A (en) 1995-02-01 1996-01-04 Stable oral pharmaceutical composition containing an acid labile benzimidazole
AR10105196A AR002702A1 (es) 1995-02-01 1996-01-17 Formulación farmacéutica oral estable conteniendo un compuesto de bencimidazol labil en medio ácido su procedimiento de obtención y sus formulaciones galenicas
IN104CA1996 IN186596B (cg-RX-API-DMAC10.html) 1995-02-01 1996-01-22
DE69634613T DE69634613T2 (de) 1995-02-01 1996-01-26 Neue stabilisierte galenische Formulierungen enthaltend ein säureempfindliches Benzimidazol und Verfahren zu ihrer Herstellung
PT99116334T PT993830E (pt) 1995-02-01 1996-01-26 Novas formulacoes galenicas estabilizadas compreendendo um composto acido labil de benzimidazole e a sua preparacao
ES96901349T ES2148725T3 (es) 1995-02-01 1996-01-26 Nuevas formulaciones galenicas estables conteniendo un compuesto de bencimidazol acido-labil, y su proceso de obtencion.
EP99116334A EP0993830B1 (en) 1995-02-01 1996-01-26 New stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
TW085100946A TW503115B (en) 1995-02-01 1996-01-26 New stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
SI9630710T SI0993830T1 (en) 1995-02-01 1996-01-26 New stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
DE29623938U DE29623938U1 (de) 1995-02-01 1996-01-26 Neue stabile galenische Formulierungen, enthaltend eine säureempfindliche Benzimidazolverbindung
SI9630226T SI0773025T1 (en) 1995-02-01 1996-01-26 New stable galenic formulations containing an acid-labile benzimidazol compound, and production process
HU9603014A HU229219B1 (en) 1995-02-01 1996-01-26 Stabilized galenic compositions containing benzimidazol derivatives decomposing in acidic medium, and process for producing them
CA002184842A CA2184842C (en) 1995-02-01 1996-01-26 New stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
KR1019960704702A KR100331290B1 (ko) 1995-02-01 1996-01-26 산에불안정한벤즈이미다졸화합물을포함하는신규의안정화된갈레닉(Galenic)제제및그의제조방법
PCT/ES1996/000013 WO1996023500A1 (es) 1995-02-01 1996-01-26 Nuevas formulaciones galenicas estables conteniendo un compuesto de bencimidazol acido-labil, y su proceso de obtencion
AU45403/96A AU4540396A (en) 1995-02-01 1996-01-26 New stable ganelic formulations containing an acid-labile benzimidazol compound, and production process
JP52327896A JP4183746B2 (ja) 1995-02-01 1996-01-26 酸不安定性ベンズイミダゾールを含有する新規安定型ガレニック製剤、及びその製造方法
DK96901349T DK0773025T3 (da) 1995-02-01 1996-01-26 Nye stabile galeniske formuleringer indeholdende en syrelabil benzimidazolforbindelser, og fremgangsmåde til fremstilling
PT96901349T PT773025E (pt) 1995-02-01 1996-01-26 Novas formulacoes galenicas estaveis que contem um composto de benzimidazol acido-labil e processo de preparacao.
DE69608767T DE69608767D1 (de) 1995-02-01 1996-01-26 Neue stabile galenische formulierungen, die eine säurelabile benzimidazolverbindung enthalten, und herstellungsverfahren
DK99116334T DK0993830T3 (da) 1995-02-01 1996-01-26 Nye stabiliserede galeniske formuleringer indeholdende en syrelabil benzimidazolforbindselse og fremgangsmåde til fremstilling heraf
ES99116334T ES2238796T3 (es) 1995-02-01 1996-01-26 Nuevas formulaciones galenicas estabilizadas que comprenden un compuesto de bencimidazol labil en medio acido y su preparacion.
AT99116334T ATE292967T1 (de) 1995-02-01 1996-01-26 Neue stabilisierte galenische formulierungen enthaltend ein säureempfindliches benzimidazol und verfahren zu ihrer herstellung
AT96901349T ATE193649T1 (de) 1995-02-01 1996-01-26 Neue stabile galenische formulierungen, die eine säurelabile benzimidazolverbindung enthalten, und herstellungsverfahren
EP96901349A EP0773025B1 (en) 1995-02-01 1996-01-26 New stable galenic formulations containing an acid-labile benzimidazol compound, and production process
ZA96683A ZA96683B (en) 1995-02-01 1996-01-30 New stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
FI963916A FI121730B (fi) 1995-02-01 1996-09-30 Uudet stabiloidut galeeniset formulaatiot, jotka sisältävät happolabiilia bentsimidatsoliyhdistettä, ja niiden valmistus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09500181A ES2094694B1 (es) 1995-02-01 1995-02-01 Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.

Publications (2)

Publication Number Publication Date
ES2094694A1 ES2094694A1 (es) 1997-01-16
ES2094694B1 true ES2094694B1 (es) 1997-12-16

Family

ID=8289322

Family Applications (3)

Application Number Title Priority Date Filing Date
ES09500181A Expired - Fee Related ES2094694B1 (es) 1995-02-01 1995-02-01 Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
ES99116334T Expired - Lifetime ES2238796T3 (es) 1995-02-01 1996-01-26 Nuevas formulaciones galenicas estabilizadas que comprenden un compuesto de bencimidazol labil en medio acido y su preparacion.
ES96901349T Expired - Lifetime ES2148725T3 (es) 1995-02-01 1996-01-26 Nuevas formulaciones galenicas estables conteniendo un compuesto de bencimidazol acido-labil, y su proceso de obtencion.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES99116334T Expired - Lifetime ES2238796T3 (es) 1995-02-01 1996-01-26 Nuevas formulaciones galenicas estabilizadas que comprenden un compuesto de bencimidazol labil en medio acido y su preparacion.
ES96901349T Expired - Lifetime ES2148725T3 (es) 1995-02-01 1996-01-26 Nuevas formulaciones galenicas estables conteniendo un compuesto de bencimidazol acido-labil, y su proceso de obtencion.

Country Status (20)

Country Link
US (1) US5626875A (cg-RX-API-DMAC10.html)
EP (2) EP0773025B1 (cg-RX-API-DMAC10.html)
JP (1) JP4183746B2 (cg-RX-API-DMAC10.html)
KR (1) KR100331290B1 (cg-RX-API-DMAC10.html)
AR (1) AR002702A1 (cg-RX-API-DMAC10.html)
AT (2) ATE193649T1 (cg-RX-API-DMAC10.html)
AU (1) AU4540396A (cg-RX-API-DMAC10.html)
CA (1) CA2184842C (cg-RX-API-DMAC10.html)
DE (3) DE29623938U1 (cg-RX-API-DMAC10.html)
DK (2) DK0773025T3 (cg-RX-API-DMAC10.html)
ES (3) ES2094694B1 (cg-RX-API-DMAC10.html)
FI (1) FI121730B (cg-RX-API-DMAC10.html)
HU (1) HU229219B1 (cg-RX-API-DMAC10.html)
IL (1) IL116673A (cg-RX-API-DMAC10.html)
IN (1) IN186596B (cg-RX-API-DMAC10.html)
PT (2) PT993830E (cg-RX-API-DMAC10.html)
SI (2) SI0993830T1 (cg-RX-API-DMAC10.html)
TW (1) TW503115B (cg-RX-API-DMAC10.html)
WO (1) WO1996023500A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA96683B (cg-RX-API-DMAC10.html)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
DK0859612T3 (da) * 1995-09-21 2003-09-22 Pharma Pass Ii Llc Farmaceutisk sammensætning indeholdende en syre-labil omeprazol og fremgangsmåde til fremstilling deraf
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
FR2774288B1 (fr) † 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
WO1999053918A1 (en) * 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
DK1105105T3 (da) * 1998-08-12 2006-07-17 Altana Pharma Ag Oral administrationsform til pyridin-2-ylmethylsulfinyl-1H-benzimidazoler
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
WO2001028559A1 (en) 1999-10-20 2001-04-26 Eisai Co., Ltd. Method for stabilizing benzimidazole compounds
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
DK1108425T3 (da) * 1999-12-16 2005-09-26 Medinfar Produtos Farmaceutico Nye, stabile flerenhedspræparater, der indeholder substituerede benzimidazoler
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
AU2002219071A1 (en) * 2000-11-10 2002-05-21 F.Hoffman-La Roche Ag Compositions containing hydrolytically unstable compositions
US20030022909A1 (en) * 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
SK287245B6 (sk) 2001-07-16 2010-04-07 Janssen Pharmaceutica N. V. Zlepšený spôsob prípravy zlúčenín benzimidazolového typu
CN1592610A (zh) * 2001-09-28 2005-03-09 麦克内尔-Ppc股份有限公司 改良的释放剂型
US20040170689A1 (en) * 2001-11-09 2004-09-02 Odink Debra Alida Stabilized formulations comprising hydrolytically unstable compositions
ES2198195B1 (es) 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
WO2004014345A1 (en) * 2002-08-02 2004-02-19 Ratiopharm Gmbh Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP1594479A1 (en) * 2003-01-31 2005-11-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
CN1767830A (zh) * 2003-04-08 2006-05-03 普罗热尼奇制药公司 外周阿片拮抗剂具体是甲基纳曲酮治疗肠易激综合征的用途
JP2006522819A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 緩下薬および末梢オピオイドアンタゴニストを組み合わせた便秘の組み合わせ療法
EP2368553B1 (en) * 2003-04-08 2014-12-31 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
WO2004098573A1 (en) * 2003-05-08 2004-11-18 Natco Pharma Limited An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
JPWO2005011637A1 (ja) * 2003-08-04 2006-09-14 エーザイ株式会社 用時分散型製剤
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005034924A1 (en) * 2003-10-14 2005-04-21 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
JP2007526319A (ja) * 2004-03-03 2007-09-13 テバ ファーマシューティカル インダストリーズ リミティド 酸不安定性薬物を含んでなる安定な医薬組成物
HRP20120049T1 (hr) 2004-05-07 2012-02-29 Nycomed Gmbh Farmaceutski dozirni oblik koji obuhvaća pilule kao i postupak njegove proizvodnje
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
EP1830823A2 (en) 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
MX2007008141A (es) * 2005-01-03 2007-12-10 Lupin Ltd Composicion farmaceutica de sustancias labiles en medio acido.
AU2006206454A1 (en) * 2005-01-20 2006-07-27 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
EP1845982A2 (en) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
EP1785135A1 (en) 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
CA2633825A1 (en) * 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
ES2511792T3 (es) * 2006-07-25 2014-10-23 Vecta Ltd. Composiciones y métodos para la inhibición de la secreción de ácido gástrico usando derivados de pequeños ácidos dicarboxílicos en combinación con IBP
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
CN101959892B (zh) * 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
JP5985824B2 (ja) 2008-07-01 2016-09-06 ザ ユニヴァーシティー オヴ シカゴ オピオイド受容体アンタゴニスト含有の粒子および使用方法
WO2010018175A2 (en) * 2008-08-11 2010-02-18 Mepha Ag Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
CH699302B1 (de) * 2008-08-11 2012-03-15 Mepha Gmbh Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht.
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
US20130202688A1 (en) 2010-05-04 2013-08-08 Sunilendu Bhushan Roy Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
PT2773348T (pt) * 2011-11-02 2018-04-16 Esteve Labor Dr Composição farmacêutica de omeprazol
GB2513172A (en) * 2013-04-18 2014-10-22 Nupharm Lab Ltd Liquid dosage form and delivery system
WO2016061531A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB829055A (en) * 1958-02-07 1960-02-24 Charles E Frosst And Company Improvements in or relating to pharmaceutical preparations
US4150111A (en) * 1974-05-28 1979-04-17 Allister Warren Enteric coated magnesium chloride
JPS5837285B2 (ja) * 1975-05-29 1983-08-15 カブシキガイシヤ ミドリジユウジ チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ
JPS5598120A (en) * 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
US4470980A (en) * 1980-03-07 1984-09-11 Interx Research Corp. Method of increasing oral absorption of β-lactam antibiotics
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
JPS58208155A (ja) * 1982-05-28 1983-12-03 Sumitomo Electric Ind Ltd 光伝送用ガラスフアイバの製造方法
JPS59193831A (ja) * 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製造法
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5395611A (en) * 1990-04-24 1995-03-07 The Governors Of The University Of Alberta Phenolic amine depigmenting and antimelanoma agents
IT1241740B (it) * 1990-06-22 1994-02-01 Edi Bondioli Protezione per una forcella di estremita' di un albero cardanico
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
DE69127275T2 (de) * 1991-06-21 1998-03-12 Ilsan Ilac Ve Hammaddeleri San Neues galenisches Verfahren für Omeprazol enthaltende Pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) * 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process

Also Published As

Publication number Publication date
ES2148725T3 (es) 2000-10-16
PT773025E (pt) 2000-10-31
EP0773025A1 (en) 1997-05-14
DK0773025T3 (da) 2000-10-09
HU229219B1 (en) 2013-09-30
EP0773025B1 (en) 2000-06-07
HUP9603014A3 (en) 2000-12-28
KR100331290B1 (ko) 2002-11-22
SI0993830T1 (en) 2005-10-31
EP0993830A2 (en) 2000-04-19
ES2238796T3 (es) 2005-09-01
DK0993830T3 (da) 2005-08-08
HUP9603014A2 (hu) 1998-03-30
IL116673A (en) 2000-10-31
DE29623938U1 (de) 2000-10-05
DE69634613T2 (de) 2006-03-09
ZA96683B (en) 1997-09-23
EP0993830A3 (en) 2001-10-04
JP4183746B2 (ja) 2008-11-19
DE69634613D1 (de) 2005-05-19
ATE292967T1 (de) 2005-04-15
SI0773025T1 (en) 2000-10-31
ATE193649T1 (de) 2000-06-15
AU4540396A (en) 1996-08-21
JPH09511257A (ja) 1997-11-11
TW503115B (en) 2002-09-21
CA2184842C (en) 2007-08-07
AR002702A1 (es) 1998-04-29
FI121730B (fi) 2011-03-31
ES2094694A1 (es) 1997-01-16
EP0993830B1 (en) 2005-04-13
CA2184842A1 (en) 1996-08-08
IL116673A0 (en) 1996-05-14
PT993830E (pt) 2005-06-30
WO1996023500A1 (es) 1996-08-08
IN186596B (cg-RX-API-DMAC10.html) 2001-10-06
FI963916A0 (fi) 1996-09-30
FI963916L (fi) 1996-09-30
DE69608767D1 (de) 2000-07-13
US5626875A (en) 1997-05-06

Similar Documents

Publication Publication Date Title
ES2094694B1 (es) Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
PE20010053A1 (es) Formulacion de amoxicilina y clavulanato de potasio
PA8456401A1 (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion
ES2101082T3 (es) Composiciones de liberacion controlada.
ES2130638T3 (es) Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas.
YU47204B (sh) Derivati didehidro-vitamina d3
AR011846A1 (es) Una composicion farmaceutica, y el procedimiento para prepararla
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
CY1107899T1 (el) 6.αλφα., 9.αλφα. - διφθορο-17.αλφα.-(2-φουρανυλοανθρακοξυλικο) οξυ-11.βητα.-υδροξυ-16.αλφα.-μεθυλο-3-οξο-ανδροστα-1,4-διενιο-17-ανθρακοθειϊκο οξυ s-φθορομεθυλο εστερας ως αντιφλεγμονωδης παραγοντας
DE60312333D1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
AR006484A1 (es) Composición farmacéutica con efecto anestésico, uso de esta composición para la fabricación de medicamentos, y proceso para la fabricación de esta composición .
MX9605888A (es) Agente esterilizante a temperatura ambiente.
ES2089277T3 (es) Uso de material de nucleo especifico y capas para obtener formulaciones farmaceuticas estables a la decoloracion de compuestos labiles a los acidos.
AR018109A1 (es) FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA
ES2197792B1 (es) Formulaciones farmaceuticas que contienen morfina intranasal.
ATE372107T1 (de) Befeuchtungsmittel und dieses enthaltende kosmetika und topische präparate
PT916347E (pt) Solucoes farmaceuticas injectaveis contendo paracetamol e combinacoes de paracetamol com outras substancias activas
ES2046176T3 (es) Composicion farmaceutica que contiene una asociacion de colageno y de un principio activo antiseptico y/o antiinflamatorio y su procedimiento de fabricacion.
ES2175362T3 (es) Agente fitosanitario solido.
ES2046852T3 (es) Un procedimiento para preparar un champu.
DK1157030T3 (da) Enchinocanidin/carbohydratkomplekser
EE03743B1 (et) Välispidine lokaalanesteetikum
ES2143481T3 (es) Comprimido de valproato de sodio de liberacion lenta.
AR002743A1 (es) Esmalte de unas, y la utilizacion de dicho esmalte para la preparacion de un medicamento para el tratamiento de onicomicosis.
DK0727996T3 (da) Fendazolformuleringer

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19970116

Kind code of ref document: A1

Effective date: 19970116

PC2A Transfer of patent
GC2A Exploitation certificate registered application with search report

Effective date: 19990506

GD2A Contractual licences

Effective date: 20000120

FD2A Announcement of lapse in spain

Effective date: 20180806